Enchannel
EnChannel Medical is a cardiac technology company founded in 2020, with headquarters in Guangzhou, China, and a subsidiary in Irvine, CA. They are dedicated to advancing electrophysiology by developing next-generation solutions for treating complex cardiac arrhythmias. Their core offerings include the DePolar™ mapping system, which features hybrid magnetic and impedance navigation, integrated contact and non-contact mapping, and AI-powered algorithms, and the NanoAblate™ PFA platform, a third-generation Pulsed Field Ablation system with both single-shot and large-focal catheter capabilities. These integrated products aim to provide personalized atrial fibrillation (AF) treatment by precisely identifying and non-thermally destroying arrhythmia sources, ultimately enhancing patient quality of life with safer and more effective treatments.
Enchannel
EnChannel Medical is a cardiac technology company founded in 2020, with headquarters in Guangzhou, China, and a subsidiary in Irvine, CA. They are dedicated to advancing electrophysiology by developing next-generation solutions for treating complex cardiac arrhythmias. Their core offerings include the DePolar™ mapping system, which features hybrid magnetic and impedance navigation, integrated contact and non-contact mapping, and AI-powered algorithms, and the NanoAblate™ PFA platform, a third-generation Pulsed Field Ablation system with both single-shot and large-focal catheter capabilities. These integrated products aim to provide personalized atrial fibrillation (AF) treatment by precisely identifying and non-thermally destroying arrhythmia sources, ultimately enhancing patient quality of life with safer and more effective treatments.